GlassScriptPhysician profile
Theresa Evans
NPI 1477012029
$2,519.04
in general payments reported to CMS, 2019-2025
37 companies · $849 in 2025
The $849 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $372 · 2024: $1,298 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,420 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,420.04 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $291.55 | 2023-2025 | |
| Pfizer INC. | $250.36 | 2023-2025 | |
| Genentech USA, INC. | $171.84 | 2023-2025 | Tecentriq, Polivy, Lunsumio |
| Genzyme Corporation | $162.57 | 2024-2025 | |
| Abbvie INC. | $137.40 | 2024-2025 | |
| Janssen Biotech, INC. | $135.32 | 2024-2025 | Rybrevant, Carvykti, Tecvayli |
| Celgene Corporation | $123.45 | 2023-2025 | Reblozyl, Pomalyst, Breyanzi |
| Exelixis INC. | $121.65 | 2023 | Cabometyx |
| Array Biopharma INC | $106.93 | 2023-2025 | Mektovi, Braftovi, Lorbrena |
| E.R. Squibb & Sons, L.L.C. | $102.01 | 2024-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $93.06 | 2024-2025 | Enhertu, Imfinzi |
| Emd Serono, INC. | $70.06 | 2024-2025 | |
| Daiichi Sankyo INC. | $62.40 | 2024-2025 | Enhertu, Datroway |
| Servier Pharmaceuticals LLC | $59.97 | 2023-2024 | |
| Gilead Sciences, INC. | $50.85 | 2023-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $46.71 | 2024 | Fruzaqla, Adynovate |
| Merck Sharp & Dohme LLC | $44.02 | 2025 | Keytruda, Welireg, Reblozyl |
| Eisai INC. | $40.65 | 2024 | |
| Pharmaessentia USA Corporation | $38.91 | 2023-2025 | Besremi |
| Incyte Corporation | $33.78 | 2024-2025 | Niktimvo, Jakafi, Pemazyre |
| Stemline Therapeutics INC. | $31.99 | 2025 | Orserdu |
| Karyopharm Therapeutics INC. | $30.16 | 2023-2024 | Xpovio |
| Ipsen Biopharmaceuticals, INC | $29.59 | 2024-2025 | Onivyde, Somatuline Depot |
| Mirati Therapeutics, INC. | $24.92 | 2024 | Krazati |
| Immunogen, INC. | $24.15 | 2023 | Elahere |
| Astellas Pharma US INC | $24.02 | 2024 | Cresemba |
| Beone Medicines USA, INC. | $22.87 | 2025 | Tevimbra |
| Adaptive Biotechnologies Corporation | $22.65 | 2024 | Clonoseq |
| Taiho Oncology, INC. | $21.46 | 2025 | |
| Lilly USA, LLC | $20.48 | 2024 | Retevmo, Jaypirca, Verzenio |
| Tolmar, INC. | $18.56 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $18.56 | 2025 | Rubraca |
| Aadi Bioscience, INC. | $18.27 | 2023 | Fyarro |
| Geron Corporation | $18.10 | 2025 | Rytelo |
| Novocure INC. | $17.92 | 2025 | Optune Lua (Novottf-200t) |
| Coherus Oncology, INC. | $16.02 | 2024 | |
| Caris Mpi, INC. | $15.83 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theresa Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.